Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/105365 |
Resumo: | FCT/MEC (UID/QUI/50006/2019). ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007265). |
id |
RCAP_edf11316b2156acb0435afe606708ca4 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/105365 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modellingDoxorubicin deliveryGalactosylated nanoparticlesHepatocyte targeting nanoparticlesMolecular modelling for drug targetingSurface modified plga nanoparticlesChemistry(all)Polymers and PlasticsFCT/MEC (UID/QUI/50006/2019). ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007265).Doxorubicin-loaded PLGA nanoparticles conjugated with a new galactose-based ligand for the specific recognition by human hepatoma cellular carcinoma cells (Hep G2) were successfully produced. The new targeting compound was selected using molecular docking combined with quantum chemical calculations for modelling and comparing molecular interactions among the H1 subunit of the asialoglycoprotein receptor containing the carbohydrate recognition domain and the ligand. The ligand, bis(1-O-ethyl-β-D-galactopyranosyl)amine, was synthetized, characterized, and subsequently linked to PLGA. Unloaded (PLGA-di-GAL NP) and doxorubicin-loaded (DOX-PLGA-di-GAL NP) nanoparticles were prepared using an emulsion method and characterized. The produced DOX-PLGA-di-GAL NP are spherical in shape with a size of 258 ± 47 nm, a zeta potential of-62.3 mV, and a drug encapsulation efficiency of 83%. The in vitro drug release results obtained show a three-phase release profile. In vitro cell studies confirmed the interaction between Hep G2 cells and PLGA-di-GAL NP. Cell cytotoxicity tests showed that unloaded NP are nontoxic and that DOX-PLGA-di-GAL NP caused a decrease of around 80% in cellular viability. The strategy used in this work to design new targeting compounds represents a promising tool to develop eective hepatocyte targeting drug delivery systems and can be applied to other tissues/organs.DQ - Departamento de QuímicaLAQV@REQUIMTEInstituto de Tecnologia Química e Biológica António Xavier (ITQB)RUNRaposo, Cláudia D.Costa, RitaPetrova, Krasimira T.Brito, CatarinaScotti, Marcus T.Cardoso, M. Margarida2020-10-09T22:47:44Z2020-01-042020-01-04T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/105365eng1618-7229PURE: 17108233https://doi.org/10.3390/polym12010094info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:50:36Zoai:run.unl.pt:10362/105365Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:40:26.352Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
title |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
spellingShingle |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling Raposo, Cláudia D. Doxorubicin delivery Galactosylated nanoparticles Hepatocyte targeting nanoparticles Molecular modelling for drug targeting Surface modified plga nanoparticles Chemistry(all) Polymers and Plastics |
title_short |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
title_full |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
title_fullStr |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
title_full_unstemmed |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
title_sort |
Development of novel galactosylated PLGA nanoparticles for hepatocyte targeting using molecular modelling |
author |
Raposo, Cláudia D. |
author_facet |
Raposo, Cláudia D. Costa, Rita Petrova, Krasimira T. Brito, Catarina Scotti, Marcus T. Cardoso, M. Margarida |
author_role |
author |
author2 |
Costa, Rita Petrova, Krasimira T. Brito, Catarina Scotti, Marcus T. Cardoso, M. Margarida |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
DQ - Departamento de Química LAQV@REQUIMTE Instituto de Tecnologia Química e Biológica António Xavier (ITQB) RUN |
dc.contributor.author.fl_str_mv |
Raposo, Cláudia D. Costa, Rita Petrova, Krasimira T. Brito, Catarina Scotti, Marcus T. Cardoso, M. Margarida |
dc.subject.por.fl_str_mv |
Doxorubicin delivery Galactosylated nanoparticles Hepatocyte targeting nanoparticles Molecular modelling for drug targeting Surface modified plga nanoparticles Chemistry(all) Polymers and Plastics |
topic |
Doxorubicin delivery Galactosylated nanoparticles Hepatocyte targeting nanoparticles Molecular modelling for drug targeting Surface modified plga nanoparticles Chemistry(all) Polymers and Plastics |
description |
FCT/MEC (UID/QUI/50006/2019). ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007265). |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-10-09T22:47:44Z 2020-01-04 2020-01-04T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/105365 |
url |
http://hdl.handle.net/10362/105365 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1618-7229 PURE: 17108233 https://doi.org/10.3390/polym12010094 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138019403366400 |